<\/p>\n
Prof. Dr. Altunta\u015f, 21 Nisan Akut Miyeloid L\u00f6semi D\u00fcnya Fark\u0131ndal\u0131k G\u00fcn\u00fc dolay\u0131s\u0131yla yapt\u0131\u011f\u0131 yaz\u0131l\u0131 a\u00e7\u0131klamada, Akut Miyeloblastik L\u00f6seminin bir t\u00fcr kan kanseri oldu\u011funu belirtti.<\/p>\n
“Bug\u00fcn 21 Nisan, Akut Miyeloid L\u00f6semi D\u00fcnya Fark\u0131ndal\u0131k G\u00fcn\u00fc. D\u00fcnyan\u0131n her yerinden insanlar\u0131n bu kanser hakk\u0131nda fark\u0131ndal\u0131k olu\u015fturmak, bilgilendirme ve bilin\u00e7lendirme yapmak i\u00e7in bir araya geldi\u011fi bir g\u00fcnd\u00fcr.” ifadesini kullanan Prof. Dr. Altunta\u015f, AML’nin bir t\u00fcr kan kanseri oldu\u011funu ve kan h\u00fccrelerinin \u00fcretildi\u011fi kemik ili\u011fi ve dolay\u0131s\u0131yla kan\u0131 etkileyen bir kanser t\u00fcr\u00fc oldu\u011funu kaydetti.<\/p>\n
Kemik ili\u011finde \u00fcretilen kan h\u00fccrelerinin kontrol d\u0131\u015f\u0131 a\u015f\u0131r\u0131 \u00e7o\u011falmaya ba\u015flad\u0131\u011f\u0131 zaman l\u00f6seminin ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131, l\u00f6seminin yeti\u015fkinlerde 10 kat daha fazla g\u00f6r\u00fcld\u00fc\u011f\u00fcn\u00fc aktaran Fevzi Altunta\u015f, “Eri\u015fkinlerde en s\u0131k g\u00f6zlenen akut l\u00f6semi t\u00fcr\u00fc Akut Miyeloid L\u00f6semidir.” ifadesine yer verdi.<\/p>\n
Daha \u00f6nce al\u0131nan kanser tedavisi, genetik hastal\u0131k ve molek\u00fcler bozukluklar, baz\u0131 kan hastal\u0131klar\u0131, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi bozukluklar\u0131, y\u00fcksek d\u00fczeyde \u0131\u015f\u0131na maruz kalman\u0131n, benzen gibi baz\u0131 kimyasallara maruz kalman\u0131n, sigara, obezite, ailede l\u00f6semi \u00f6yk\u00fcs\u00fc ve baz\u0131 vir\u00fcslerin l\u00f6semi riskini art\u0131rabilece\u011fini belirten Altunta\u015f, bu risk fakt\u00f6rlerini ortadan kald\u0131rman\u0131n veya azaltman\u0131n l\u00f6semi geli\u015fim riskini de azaltabilece\u011fini vurgulad\u0131.<\/p>\n
– “Ba\u015far\u0131 oran\u0131 y\u00fczde 60’lar\u0131 a\u015ft\u0131”<\/p>\n
L\u00f6semide yenilik\u00e7i yakla\u015f\u0131mlarla ba\u015far\u0131 oranlar\u0131n\u0131n y\u00fczde 60’lar\u0131 a\u015ft\u0131\u011f\u0131n\u0131, bu ba\u011flamda bireyselle\u015ftirilmi\u015f tedavinin gerekli oldu\u011funu ifadesini kullanan Prof. Dr. Altunta\u015f, l\u00f6semi tedavisinde son 30 y\u0131la bak\u0131ld\u0131\u011f\u0131nda genel anlamda y\u00fczde 10’larda olan ba\u015far\u0131 oran\u0131n\u0131n bug\u00fcn y\u00fczde 30’lar\u0131n \u00fczerine \u00e7\u0131kt\u0131\u011f\u0131n\u0131, baz\u0131 alt gruplarda da 60’lar\u0131 ge\u00e7ti\u011fini kaydetti.<\/p>\n
Altunta\u015f, klinik ara\u015ft\u0131rmalar sonucu, hastal\u0131k nedeniyle \u00f6l\u00fcm oranlar\u0131n\u0131n y\u00fczde 0,5 oran\u0131nda azald\u0131\u011f\u0131n\u0131 belirterek, “Hastalar a\u00e7\u0131s\u0131ndan yenilik\u00e7i tedavilere ula\u015f\u0131m bir \u015fanst\u0131r, bunun asla ‘denek’ gibi alg\u0131lanmamas\u0131 laz\u0131m. Standart tedavileri t\u00fcketen her hasta yenilik\u00e7i tedavilere eri\u015fim i\u00e7in klinik ara\u015ft\u0131rmalara kat\u0131lmal\u0131d\u0131r.” de\u011ferlendirmesini yapt\u0131.<\/p>\n